Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2022 | Evolving strategies in mHSPC

Silke Gillessen • 18 Oct 2022
PROSCA/BLADDR 2022
Genitourinary Cancer Prostate Cancer Abiraterone Docetaxel Enzalutamide

Silke Gillessen, MD, PhD, University of Lugano and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses evolving strategies in metastatic hormone-sensitive prostate cancer (mHSPC), including treatment intensification with chemotherapy. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Silke Gillessen

2:30
PARP inhibitors plus novel endocrine agents for patients with metastatic prostate cancer
Silke Gillessen • 18 Feb 2023
1:23
The role of immune checkpoint inhibitors in mCRPC
Silke Gillessen • 18 Feb 2023
2:12
Criteria for treatment selection for patients with CRPC
Silke Gillessen • 18 Feb 2023
2:43
Treatment sequencing and combinations for prostate cancer
Silke Gillessen • 18 Feb 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals